NextCure Inc.

11/20/2026 | Press release | Distributed by Public on 11/20/2026 06:30

Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

​

On November 16, 2026, NextCure, Inc. (the "Company", "we", "us", or "our") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying us that we were not in compliance with the minimum stockholders' equity requirement applicable to companies listed on the Nasdaq Global Select Market under Listing Rule 5450(b)(1)(A) (the "Minimum Stockholders' Equity Requirement"), because the Company's stockholders' equity of $5,503,000, as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, was below the required minimum of $10.0 million, and because, as of November 16, 2026, the Company did not meet the alternative compliance standards relating to the market value of the listed securities or the Company's total assets and revenue.

​

In accordance with Nasdaq Listing Rule 5810(c)(2)(C), we have 45 calendar days, or until January 4, 2027, to submit a plan to regain compliance with the Minimum Stockholders' Equity Requirement (the "Grace Period"). The closing of the Company's previously announced proposed merger (the "Merger") with Avere Therapeutics, Inc. ("Avere") is expected to occur in mid-December 2026, subject to stockholder approval and other customary closing conditions, which is before the Grace Period ends. The Company believes that consummation of the Merger prior to the expiration of the Grace Period would result in the Company regaining compliance with the Minimum Stockholders' Equity Requirement and, therefore, may eliminate the need to submit a compliance plan to Nasdaq. If the Merger is not completed before the Grace Period ends, the Company intends to submit a plan to regain compliance.

The Notice has no immediate effect on the listing or trading of our common stock, which will continue to be listed and traded on the Nasdaq Global Select Market, subject to our compliance with other Nasdaq listing requirements. There can be no assurance that the Company will be able to regain compliance with the Minimum Stockholders' Equity Requirement or maintain compliance with the other Nasdaq listing requirements.

​

NextCure Inc. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 20, 2026 at 12:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]